Skip to content

Effects of a dairy ingredient on vaginal environment in postmenopausal women: a randomized, double-blind, placebo-controlled trial

Effects of a dairy ingredient on vaginal environment in postmenopausal women: a randomized, double-blind, placebo-controlled trial - Effects of a dairy ingredient on vaginal environment in postmenopausal women

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000056312
Enrollment
80
Registered
2024-11-29
Start date
2025-01-08
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None (Healthy subjects)

Interventions

Ingestion of dairy ingredient for 12 weeks Ingestion of placebo for 12 weeks

Sponsors

Bunkyo Garden Women's Clinic
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1)Female subjects 2)Subjects between 50 to 65 years old 3)More than 1 year has passed since the last menstrual period

Exclusion criteria

Exclusion criteria: 1)Subjects diagnosed with bacterial vaginosis within the past 3 months 2)Subjects with Nugent score of 7 or higher 3)Subjects who have received oral or intravenous antibiotic treatment within the past 3 months from the time of screening 4)Subjects who plan to make major lifestyle changes (diet, sleep, exercise, etc.) during the study period 5)Subjects having a milk allergy 6)Subjects who regularly consume foods containing a dairy ingredient to be evaluated 7)Subjects who have serious disease in the liver, kidney heart, lung, gastrointestinal tract, blood, endocrine system, or metabolic system etc. Or those who have serious medical history of these 8)Subjects who have medical history of drug allergy or severe food allergy 9)Others who have been determined as ineligible for the research subject of this study, judging by the principal investigator on the findings of their background, physical observations, physical examination, and so on

Design outcomes

Primary

MeasureTime frame
Nugent score

Secondary

MeasureTime frame
Nugent subscore

Countries

Japan

Contacts

Public ContactTamaki Furuhata

EP Mediate Co., Ltd. Development Department Trial Planning Section

furuhata.tamaki686@eps.co.jp070-3023-8207

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026